Luma Sciences: Illuminating the Future of Diagnostics from Cardiff

Tucked into Cardiff's growing health and technology corridor, Luma Sciences has spent the past six years developing photonics-based diagnostic tools that promise faster, less invasive ways to detect disease. Founded in 2019 by a trio of researchers from Cardiff University's School of Physics and Astronomy, the company has grown from a university spinout with a single proof-of-concept device into a team of around 140 people working across hardware engineering, software, clinical partnerships, and regulatory affairs.

The company's core technology uses advanced spectral analysis, combining low-power laser systems with machine learning models to identify biomarkers in tissue and fluid samples. Where traditional lab diagnostics can take hours or days, Luma's devices aim to deliver results at the point of care within minutes. It is a bold goal, and one that has attracted both NHS pilot partnerships and attention from European healthcare networks seeking to reduce bottlenecks in pathology services.

From Lab Bench to Clinical Reality

Luma Sciences sits at a complicated intersection: photonics, data science, medical device regulation, and clinical need. The company's journey from laboratory prototype to CE-marked device has been anything but straightforward. Early versions of its flagship platform, the Luma Prism, required extensive recalibration between uses and struggled with ambient light interference. It took nearly two years of iterative hardware and firmware refinement before the device became reliable enough for pilot deployment in Welsh NHS trusts.

Dr. Megan Hâf, one of the co-founders and the company's chief scientific officer, has spoken openly about the difficulty of translating academic research into something a nurse or GP can use without specialist training. In a 2023 interview with MedTech Wales, she put it plainly:

"We had to stop thinking like physicists and start thinking like the people who would actually hold this device in their hands. That shift changed everything, from our UI design to how we package our calibration routines."

That user-centred philosophy now runs through most of what Luma Sciences does. Product teams are structured around clinical use cases rather than technical disciplines, meaning a software engineer working on the Prism's data pipeline might sit alongside a clinical liaison officer and a regulatory specialist on the same project squad.

Cardiff as a Strategic Home

The decision to remain headquartered in Cardiff, rather than relocating to London or Cambridge as many UK health-tech firms eventually do, has been deliberate. The company benefits from proximity to Cardiff University's optics and photonics research groups, a relationship that feeds a steady stream of postdoctoral talent into Luma's R&D division. Cardiff also offers access to the Welsh Government's life sciences funding ecosystem, which has provided both direct grants and introductions to NHS Wales clinical sites willing to participate in pilot studies.

The city's cost base has helped too. Office and lab space in Cardiff Bay, where Luma occupies two floors of a converted dockside building, runs at a fraction of comparable space in the South East. For a company still burning through venture capital on its way to profitability, that difference matters. A Series B round closed in early 2024, led by a Zurich-based health-tech fund, brought the company's total raised to approximately £38 million.

The Product Landscape

The Luma Prism remains the company's primary product, now in its third hardware generation. It is used primarily for rapid screening of inflammatory markers and certain metabolic indicators, with clinical validation studies ongoing for additional analytes. A second product line, still in development, applies similar spectral principles to dermatological assessment, using a handheld scanner to characterize skin lesions without biopsy.

Behind both devices sits a growing cloud platform, Luma Insight, which aggregates anonymised diagnostic data from deployed units. The platform serves two purposes: it enables remote monitoring and firmware updates for devices in the field, and it provides a data foundation for continuous improvement of the machine learning models that interpret spectral readings. As the installed base grows, so does the dataset, and with it the potential accuracy of the diagnostic algorithms.

Culture and Working Life

Luma Sciences is not a typical startup in temperament. The academic roots of its founding team have left a mark on company culture. Internal knowledge-sharing sessions, held fortnightly, resemble seminar presentations more than corporate town halls. Engineers are encouraged to publish findings where IP constraints allow, and several team members hold visiting researcher positions at Cardiff University.

The pace is deliberate rather than frantic. Medical device development operates under strict regulatory frameworks, and Luma's leadership has resisted the temptation to rush features to market at the expense of rigour. That said, the company moves considerably faster than a traditional medical device manufacturer, borrowing agile practices from the software world and applying them within the constraints of ISO 13485 and UKCA/CE marking requirements.

Working at Luma means accepting a degree of ambiguity. The problems are genuinely hard, spanning physics, biology, software, and human factors. Teams are small enough that individual contributions are visible, but the regulatory and clinical dimensions mean that shipping a feature is never as simple as merging a pull request. For people who thrive on complex, interdisciplinary challenges and who want their work to have a tangible effect on healthcare delivery, it is a compelling place to be.

What Comes Next

With its Series B secured and NHS pilot data beginning to show promising results, Luma Sciences is entering a pivotal phase. The next 18 months will determine whether the Prism can transition from pilot curiosity to standard clinical tool. Expansion into European markets is planned for late 2025, with Germany and the Netherlands identified as priority territories. Hiring across engineering, regulatory, and commercial functions is accelerating, with the Cardiff headquarters expected to grow to around 200 people by the end of 2025.

For a company born from a Cardiff University physics lab, the trajectory has been remarkable. Whether Luma Sciences can deliver on its promise of faster, cheaper, better diagnostics remains to be proven at scale, but the foundations, both scientific and organisational, appear solid.